Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron Under Study Protocol 1VIT17044
Latest Information Update: 22 Mar 2022
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors American Regent
Most Recent Events
- 16 Mar 2021 Status changed from recruiting to completed.
- 24 Feb 2020 New trial record